Holen Sie sich die Stockscreener-App
25.02
1.89%
0.72
Schlusskurs vom Vortag:
$24.30
Offen:
$24.34
24-Stunden-Volumen:
9,564
Relative Volume:
0.15
Marktkapitalisierung:
$524.94M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-31.67
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
-14.56%
1M Leistung:
-15.41%
6M Leistung:
+142.51%
1J Leistung:
+89.96%
1-Tages-Spanne:
$24.34
$25.03
1-Wochen-Bereich:
$24.30
$29.21
52-Wochen-Spanne:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
24.71 | 516.23M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.41 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.73 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
How rising interest rates impact Lyell Immunopharma Inc. stockJuly 2025 Momentum & Fast Exit/Entry Strategy Plans - ulpravda.ru
Will Lyell Immunopharma Inc. stock benefit from automationJuly 2025 Macro Moves & Community Consensus Trade Alerts - ulpravda.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6%Here's Why - MarketBeat
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Market Profile Overview & Low Cost Wealth Investment - bollywoodhelpline.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2%Still a Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell? - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7%Here's Why - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Yahoo Finance
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5%Here's Why - MarketBeat
Lyell ImmunoPharma pops on recent ASH data, immunotherapy expansion - MSN
Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year HighTime to Buy? - MarketBeat
Lyell Immunopharma pops on recent ASH data, immunotherapy expansion - Seeking Alpha
Why Lyell Immunopharma Inc. stock could be next big winnerPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Will Lyell Immunopharma Inc. stock rally after Fed decisionsGold Moves & High Accuracy Swing Trade Signals - Улправда
Dip Buying: Is Lyell Immunopharma Inc. stock a smart buy before Fed meeting2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
What technical charts say about Lyell Immunopharma Inc. stock2025 Trading Recap & Risk Controlled Stock Pick Alerts - DonanımHaber
What analysts say about Lyell Immunopharma Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
CEO Change: Why Lyell Immunopharma Inc. stock could be next big winnerBond Market & Consistent Profit Trading Strategies - Улправда
Can Lyell Immunopharma Inc. stock reach $100 price target2025 Earnings Impact & Daily Profit Focused Screening - DonanımHaber
Is Lyell Immunopharma Inc. stock a safe buy before earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - Улправда
Why Lyell Immunopharma Inc. stock could outperform in 20252025 Major Catalysts & Intraday High Probability Setup Alerts - DonanımHaber
Is Lyell Immunopharma Inc. stock a smart buy before Fed meetingJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - Улправда
Lyell Immunopharma (LYEL) details 1.9M-share ICT resale and license terms - Stock Titan
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
China Universal Asset Management Co. Ltd. Has $26,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World
HSG Holding Ltd Cuts Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC - MarketBeat
Lyell ImmunoPharma announces new data from trial of rondecabtagene autoleucel - MSN
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighShould You Buy? - MarketBeat
Aug Technicals: Why Lyell Immunopharma Inc stock could outperform in 2025Weekly Gains Summary & Smart Swing Trading Alerts - moha.gov.vn
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 11.4%Should You Buy? - MarketBeat
100,000 Shares in Lyell Immunopharma, Inc. $LYEL Bought by RBF Capital LLC - MarketBeat
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView — Track All Markets
Lyell Immunopharma (LYEL) price target increased by 35.71% to 19.38 - MSN
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
HC Wainwright & Co. Upgrades Lyell Immunopharma (LYEL) - Nasdaq
Lyell Immunopharma stock rises on strong cancer therapy trial data By Investing.com - Investing.com Australia
Lyell Immunopharma stock rises on strong cancer therapy trial data - Investing.com
Lyell Immunopharma Presents Promising CAR T-Cell Data - TipRanks
Lyell Immunopharma Presents New Data on Ronde-cel at ASH Meeting - TradingView — Track All Markets
LYEL FinancialsIncome Statement - Quiver Quantitative
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):